Keros Therapeutics (NASDAQ:KROS) Now Covered by Analysts at Oppenheimer

Oppenheimer initiated coverage on shares of Keros Therapeutics (NASDAQ:KROS) in a research note issued to investors on Tuesday morning, MarketBeat.com reports. The firm issued an outperform rating and a $102.00 price objective on the stock.

Other equities research analysts have also issued reports about the company. Wedbush restated an outperform rating and issued a $86.00 price objective on shares of Keros Therapeutics in a research note on Thursday, February 29th. Truist Financial reissued a buy rating and set a $100.00 price objective on shares of Keros Therapeutics in a report on Tuesday, June 18th. Piper Sandler reaffirmed an overweight rating and issued a $105.00 price target on shares of Keros Therapeutics in a report on Wednesday, March 27th. Finally, HC Wainwright reissued a buy rating and issued a $100.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, June 18th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Keros Therapeutics currently has an average rating of Buy and a consensus target price of $88.29.

Keros Therapeutics Trading Down 1.8 %

Shares of KROS opened at $45.65 on Tuesday. The firm has a market cap of $1.65 billion, a PE ratio of -8.86 and a beta of 1.25. The firm has a fifty day simple moving average of $51.98 and a two-hundred day simple moving average of $54.27. Keros Therapeutics has a 1-year low of $27.02 and a 1-year high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($1.21) EPS for the quarter, topping the consensus estimate of ($1.33) by $0.12. The company had revenue of $0.08 million during the quarter. Keros Therapeutics’s quarterly revenue was down 97.3% compared to the same quarter last year. During the same period last year, the business earned ($1.26) EPS. As a group, research analysts forecast that Keros Therapeutics will post -4.98 EPS for the current fiscal year.

Institutional Trading of Keros Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. increased its stake in shares of Keros Therapeutics by 356.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,460 shares of the company’s stock worth $138,000 after purchasing an additional 2,702 shares in the last quarter. Ameritas Investment Partners Inc. increased its stake in shares of Keros Therapeutics by 14.5% during the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after purchasing an additional 324 shares in the last quarter. Arizona State Retirement System purchased a new stake in shares of Keros Therapeutics during the fourth quarter worth about $231,000. Bayesian Capital Management LP acquired a new position in Keros Therapeutics during the first quarter worth about $267,000. Finally, CANADA LIFE ASSURANCE Co boosted its position in Keros Therapeutics by 117.8% during the first quarter. CANADA LIFE ASSURANCE Co now owns 5,217 shares of the company’s stock worth $345,000 after acquiring an additional 2,822 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.